No abstract available
MeSH terms
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / therapeutic use*
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Clinical Trials, Phase II as Topic
-
Dose-Response Relationship, Drug
-
Drugs, Investigational / adverse effects
-
Drugs, Investigational / therapeutic use*
-
Female
-
HIV Antibodies / adverse effects
-
HIV Antibodies / therapeutic use*
-
HIV Infections / drug therapy*
-
Humans
-
Injections, Intravenous
-
Injections, Subcutaneous
-
Male
-
Maximum Tolerated Dose
-
Sensitivity and Specificity
-
Treatment Outcome
Substances
-
Anti-HIV Agents
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Drugs, Investigational
-
HIV Antibodies
-
leronlimab